These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36770075)

  • 1. The Emergence of Carbon Nanomaterials as Effective Nano-Avenues to Fight against COVID-19.
    Sengupta J; Hussain CM
    Materials (Basel); 2023 Jan; 16(3):. PubMed ID: 36770075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbon nanomaterials to combat virus: A perspective in view of COVID-19.
    Sengupta J; Hussain CM
    Carbon Trends; 2021 Jan; 2():100019. PubMed ID: 38620887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era.
    Serrano-Aroca Á; Takayama K; Tuñón-Molina A; Seyran M; Hassan SS; Pal Choudhury P; Uversky VN; Lundstrom K; Adadi P; Palù G; Aljabali AAA; Chauhan G; Kandimalla R; Tambuwala MM; Lal A; Abd El-Aziz TM; Sherchan S; Barh D; Redwan EM; Bazan NG; Mishra YK; Uhal BD; Brufsky A
    ACS Nano; 2021 May; 15(5):8069-8086. PubMed ID: 33826850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbon nanotube field-effect transistor (CNT-FET)-based biosensor for rapid detection of SARS-CoV-2 (COVID-19) surface spike protein S1.
    Zamzami MA; Rabbani G; Ahmad A; Basalah AA; Al-Sabban WH; Nate Ahn S; Choudhry H
    Bioelectrochemistry; 2022 Feb; 143():107982. PubMed ID: 34715586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19: Progress in diagnostics, therapy and vaccination.
    Liu X; Liu C; Liu G; Luo W; Xia N
    Theranostics; 2020; 10(17):7821-7835. PubMed ID: 32685022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbon fullerene and nanotube are probable binders to multiple targets of SARS-CoV-2: Insights from computational modeling and molecular dynamic simulation studies.
    Skariyachan S; Gopal D; Deshpande D; Joshi A; Uttarkar A; Niranjan V
    Infect Genet Evol; 2021 Dec; 96():105155. PubMed ID: 34823028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
    Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
    Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019-2020.
    Islam A; Ahmed A; Naqvi IH; Parveen S
    Virusdisease; 2020 Jun; 31(2):128-136. PubMed ID: 32292802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
    Sharma A; Tiwari S; Deb MK; Marty JL
    Int J Antimicrob Agents; 2020 Aug; 56(2):106054. PubMed ID: 32534188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon Nanostructured Immunosensing of Anti-SARS-CoV-2 S-Protein Antibodies.
    du Plooy J; Kock B; Jahed N; Iwuoha E; Pokpas K
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges.
    Mohan SV; Hemalatha M; Kopperi H; Ranjith I; Kumar AK
    Chem Eng J; 2021 Feb; 405():126893. PubMed ID: 32901196
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.